Shigellosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:810A03.8A03.9A03.0
Who is this for?
Show terms as
6Active trials32Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Shigellosis, also known as bacillary dysentery, is an acute infectious disease caused by bacteria of the genus Shigella. There are four species that cause human disease: Shigella dysenteriae (serogroup A), Shigella flexneri (serogroup B), Shigella boydii (serogroup C), and Shigella sonnei (serogroup D). The disease primarily affects the gastrointestinal system, specifically the colon and rectum, where the bacteria invade the intestinal epithelium, causing intense inflammation and mucosal destruction. Transmission occurs via the fecal-oral route, often through contaminated food, water, or direct person-to-person contact. The infectious dose is remarkably low, making it highly contagious. Key symptoms include watery or bloody diarrhea (dysentery), abdominal cramps, fever, nausea, vomiting, and tenesmus (painful straining during bowel movements). The illness typically begins 1 to 3 days after exposure and is usually self-limiting, resolving within 5 to 7 days. However, severe cases, particularly those caused by Shigella dysenteriae type 1, can lead to serious complications including hemolytic uremic syndrome (HUS), toxic megacolon, intestinal perforation, seizures (especially in young children), severe dehydration, and septicemia. Children under 5 years of age, elderly individuals, and immunocompromised patients are at greatest risk for severe disease and complications. Treatment focuses on rehydration therapy (oral or intravenous) to replace fluid and electrolyte losses. Antibiotic therapy is recommended for moderate to severe cases and can shorten the duration and severity of illness. Commonly used antibiotics include fluoroquinolones (such as ciprofloxacin), azithromycin, and third-generation cephalosporins, though antimicrobial resistance is an increasing global concern. Prevention strategies include proper hand hygiene, safe water supply, adequate sanitation, and food safety measures. No vaccine is currently widely available, though several candidates are in development.

Clinical phenotype terms— hover any for plain English:

Bloody mucoid diarrheaHP:0025086Abdominal crampsHP:0032155Abnormal blood ion concentrationHP:0003111TenesmusHP:0012702Paralytic ileusHP:0002590Bloody diarrheaHP:0025085
Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026The Impact of Shigellosis and Recommended Treatment in Children

Johns Hopkins Bloomberg School of Public Health — PHASE2

TrialRECRUITING
Jan 2026Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children

GlaxoSmithKline — PHASE2

TrialNOT YET RECRUITING
Oct 2025First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

Inventprise Inc. — PHASE1

TrialRECRUITING
Jun 2025Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

Eveliqure Biotechnologies GmbH — PHASE2

TrialRECRUITING
Apr 2025Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd — PHASE3

TrialNOT YET RECRUITING
Jan 2025Shigella Sonnei 53G Human Infection Study in Kenyan Adults

University of Oxford — PHASE1

TrialRECRUITING
Nov 2024A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

LimmaTech Biologics AG — PHASE2

TrialRECRUITING
Oct 2024InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia

Leiden University Medical Center — PHASE1

TrialRECRUITING
Feb 2023Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis

Intralytix, Inc. — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Aug 2022Enterics for Global Health (EFGH)

University of Washington

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Shigellosis.

6 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

6 recruitingView all trials with filters →
Phase 23 trials
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
Phase 2
Actively Recruiting
PI: Kawsar R Talaat, MD (Johns Hopkins Bloomberg School of Public Health) · Sites: Atlanta, Georgia; Baltimore, Maryland +1 more · Age: 1850 yrs
The Impact of Shigellosis and Recommended Treatment in Children
Phase 2
Actively Recruiting
PI: Subhra Chakraborty, PhD, MPH, MSc (Johns Hopkins Bloomberg School of Public Health) · Sites: Chāndpur; Dhaka +2 more
Tebipenem Trial in Children With Shigellosis
Phase 2
Active
PI: Sharika Nuzhat, MBBS, DCH (International Centre for Diarrhoeal Disease Resear) · Sites: Dhaka
Phase 12 trials
InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia
Phase 1
Actively Recruiting
· Sites: Leiden · Age: 1850 yrs
Shigella Sonnei 53G Human Infection Study in Kenyan Adults
Phase 1
Actively Recruiting
· Sites: Kilifi · Age: 1845 yrs

Specialists

Showing 25 of 32View all specialists →
KM
Kawsar R Talaat, MD
BALTIMORE, MD
Specialist
PI on 2 active trials
PP
Patricia Martin, PhD
Specialist
PI on 1 active trial
DM
Dr Odile Launay, MD
Specialist
PI on 1 active trial
AP
Alexander Sulakvelidze, PhD
Specialist
PI on 1 active trial
SD
Sharika Nuzhat, MBBS, DCH
Specialist
PI on 1 active trial
OP
Odile Launay, Prof
Specialist
PI on 1 active trial
WM
Wilbur Chen Chen, MD, MS
BALTIMORE, MD
Specialist
PI on 1 active trial
RP
Rubhana Raqib, Ph.D.
Specialist
PI on 1 active trial
CD
Christoph Hatz, Prof. Dr.
Specialist
PI on 1 active trial
FM
Feng-Ying C Lin, M.D.
Specialist
PI on 1 active trial
MM
Mark Riddle, MD
FPO, AE
Specialist
PI on 1 active trial
SP
Stephen Stephen, Professor
DERIDDER, LA
Specialist
PI on 1 active trial
WM
Wilbur Chen, MD, MS
BALTIMORE, MD
Specialist
PI on 3 active trials
KM
Kawsar Talaat, MD
BALTIMORE, MD
Specialist
PI on 7 active trials
MP
Mark S. Riddle, MD Dr Ph
FPO, AE
Specialist
PI on 1 active trial
KP
Katja Polman, PhD
Specialist
PI on 1 active trial
MP
Marleen Boelaert, PhD
Specialist
PI on 1 active trial
JP
Jürg Utzinger, PhD
Specialist
PI on 1 active trial
RM
Robert Frenck, MD
CINCINNATI, OH
Specialist
PI on 1 active trial
SD
Swapan Kumar Roy, MBBS, M.Sc, Ph. D
Specialist
PI on 1 active trial5 Shigellosis publications
DM
Dr David Lewis, MD
Specialist
PI on 1 active trial
FM
Fredrick Sawe, MBChB MMED
STOUGHTON, MA
Specialist
PI on 1 active trial
DP
David Tribble, MD, PhD
Specialist
PI on 1 active trial
RM
Ramiro Gutierrez, MD, MPH
EL PASO, TX
Specialist
PI on 1 active trial
KM
Karen L. Kotloff, M.D.
BALTIMORE, MD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Shigellosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open ShigellosisForum →

No community posts yet. Be the first to share your experience with Shigellosis.

Start the conversation →

Latest news about Shigellosis

Disease timeline:

New recruiting trial: Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

A new clinical trial is recruiting patients for Shigellosis

New recruiting trial: InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia

A new clinical trial is recruiting patients for Shigellosis

New recruiting trial: Shigella Sonnei 53G Human Infection Study in Kenyan Adults

A new clinical trial is recruiting patients for Shigellosis

New recruiting trial: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

A new clinical trial is recruiting patients for Shigellosis

New recruiting trial: The Impact of Shigellosis and Recommended Treatment in Children

A new clinical trial is recruiting patients for Shigellosis

New recruiting trial: First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

A new clinical trial is recruiting patients for Shigellosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Shigellosis

What is Shigellosis?

Shigellosis, also known as bacillary dysentery, is an acute infectious disease caused by bacteria of the genus Shigella. There are four species that cause human disease: Shigella dysenteriae (serogroup A), Shigella flexneri (serogroup B), Shigella boydii (serogroup C), and Shigella sonnei (serogroup D). The disease primarily affects the gastrointestinal system, specifically the colon and rectum, where the bacteria invade the intestinal epithelium, causing intense inflammation and mucosal destruction. Transmission occurs via the fecal-oral route, often through contaminated food, water, or direc

Are there clinical trials for Shigellosis?

Yes — 6 recruiting clinical trials are currently listed for Shigellosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Shigellosis?

25 specialists and care centers treating Shigellosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.